Skip to main content

Advertisement

SpringerLink
Log in

ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Purpose

Investigate ErbB family expression in colorectal cancer patients with higher risk of recurrence after surgical treatment.

Methods

We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique.

Results

The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis.

Conclusions

The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. Global Cancer Facts & Figures 2007—American Cancer Society. Available from URL: http://www.cancer.org [accessed in May 14, 2008].

  2. Nelson H, Petrelli N, Carlin A et al (2001) National Cancer Institute Expert Panel. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 93(8):583–96

    Article  PubMed  CAS  Google Scholar 

  3. Gelb AB, Schrock TR (1997) Prognostic factors in colorectal carcinomas. Surg Oncol Clin N Am 6(3):463–94

    PubMed  CAS  Google Scholar 

  4. Ratto C, Sofo L, Ippoliti M et al (1998) Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 41(8):1033–49

    Article  PubMed  CAS  Google Scholar 

  5. Compton C, Fenoglio-Preiser CM, Pettigrew N et al (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88(7):1739–57

    Article  PubMed  CAS  Google Scholar 

  6. Greene FL, Page DL, Fleming ID et al (2002) AJCC Cancer Staging Manual—6th ed. Springer-Verlag, New York

    Book  Google Scholar 

  7. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA. 1990;264(11):1444–50.

    Google Scholar 

  8. Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–19

    Article  PubMed  Google Scholar 

  9. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–37

    Article  PubMed  CAS  Google Scholar 

  10. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5(5):341–54

    Article  PubMed  CAS  Google Scholar 

  11. Grandis JR, Sok JC (2004) Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 102(1):37–46

    Article  PubMed  CAS  Google Scholar 

  12. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7(7):505–16

    Article  PubMed  CAS  Google Scholar 

  13. Finnegan TJ, Carey LA (2007) Gene-expression analysis and the basal-like breast cancer subtype. Future Oncol 3(1):55–63

    Article  PubMed  CAS  Google Scholar 

  14. Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26(45):6469–87

    Article  PubMed  CAS  Google Scholar 

  15. Sergina NV, Moasser MM (2007) The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med 13(12):527–34 Epub 2007

    Article  PubMed  CAS  Google Scholar 

  16. Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–82

    Article  PubMed  CAS  Google Scholar 

  17. Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16(6):413–28

    Article  PubMed  CAS  Google Scholar 

  18. Jeong EG, Soung YH, Lee JW et al (2006) ERBB3 kinase domain mutations are rare in lung, breast and colon carcinomas. Int J Cancer 119(12):2986–7

    Article  PubMed  CAS  Google Scholar 

  19. Karamouzis MV, Badra FA, Papavassiliou AG (2007) Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 39(5):851–6

    Article  PubMed  CAS  Google Scholar 

  20. Sartor CI, Zhou H, Kozlowska E et al (2001) Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol 21(13):4265–75

    Article  PubMed  CAS  Google Scholar 

  21. Compton C, Fenoglio-Preiser CM, Pettigrew N et al (2000) American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 88(7):1739–57

    Article  PubMed  CAS  Google Scholar 

  22. Compton C, Fielding LP, Burgart LJ et al (2000) Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):979–94

    PubMed  CAS  Google Scholar 

  23. Kountourakis P, Pavlakis K, Psyrri A et al (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46

    Article  PubMed  CAS  Google Scholar 

  24. Jacobs TW, Gown AM, Yaziji H et al (1999) Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 17(7):1983–7

    PubMed  CAS  Google Scholar 

  25. Yasui W, Sumiyoshi H, Hata J et al (1988) Expression of epidermal growth factor receptor in human gastric and colonic carcinomas. Cancer Res 48(1):137–41

    PubMed  CAS  Google Scholar 

  26. Spano JP, Lagorce C, Atlan D et al (2005) Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16(1):102–8

    Article  PubMed  Google Scholar 

  27. McKay JA, Murray LJ, Curran S et al (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38(17):2258–64

    Article  PubMed  CAS  Google Scholar 

  28. Scartozzi M, Bearzi I, Berardi R et al (2004) Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22(23):4772–8

    Article  PubMed  CAS  Google Scholar 

  29. Goldstein NS, Armin M (2001) Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92(5):1331–46

    Article  PubMed  CAS  Google Scholar 

  30. Steele RJ, Kelly P, Ellul B et al (1990) Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 77(12):1352–4

    Article  PubMed  CAS  Google Scholar 

  31. Galizia G, Lieto E, Ferraraccio F et al (2006) Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13(6):823–35

    Article  PubMed  Google Scholar 

  32. Nathanson DR, Culliford AT 4th, Shia J et al (2003) HER 2/neu expression and gene amplification in colon cancer. Int J Cancer 105(6):796–802

    Article  PubMed  CAS  Google Scholar 

  33. Schuell B, Gruenberger T, Scheithauer W et al (2006) HER 2/neu protein expression in colorectal cancer. BMC Cancer 6:123

    Article  PubMed  CAS  Google Scholar 

  34. Ochs AM, Wong L, Kakani V et al (2004) Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer 4(4):262–7

    Article  PubMed  CAS  Google Scholar 

  35. McKay JA, Loane JF, Ross VG et al (2002) c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer 86(4):568–73

    Article  PubMed  CAS  Google Scholar 

  36. Essapen S, Thomas H, Green M et al (2004) The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 24(2):241–8

    PubMed  Google Scholar 

  37. Osako T, Miyahara M, Uchino S et al (1998) Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology 55(6):548–55

    Article  PubMed  CAS  Google Scholar 

  38. Kluftinger AM, Robinson BW, Quenville NF et al (1992) Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol 1(1):97–105

    Article  PubMed  CAS  Google Scholar 

  39. Cunningham MP, Essapen S, Thomas H et al (2006) Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol 28(2):329–35

    PubMed  Google Scholar 

  40. Maurer CA, Friess H, Kretschmann B et al (1998) Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 29(8):771–7

    Article  PubMed  CAS  Google Scholar 

  41. Kapitanović S, Radosević S, Slade N et al (2000) Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol 126(4):205–11

    Article  PubMed  Google Scholar 

  42. Lee JC, Wang ST, Chow NH et al (2002) Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38(8):1065–71

    Article  PubMed  CAS  Google Scholar 

  43. Kountourakis P, Pavlakis K, Psyrri A et al (2006) Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer 6:46

    Article  PubMed  CAS  Google Scholar 

  44. Koumakpayi IH, Diallo JS, Le Page C et al (2006) Expression and nuclear localization of ErbB3 in prostate cancer. Clin Cancer Res 12(9):2730–7

    Article  PubMed  CAS  Google Scholar 

  45. Feroz K, Williams E, Riese DJ 2nd (2002) ErbB2 and ErbB3 do not quantitatively modulate ligand-induced ErbB4 tyrosine phosphorylation. Cell Signal 14(9):793–8

    Article  PubMed  CAS  Google Scholar 

  46. Zlobec I, Terracciano L, Jass JR et al (2007) Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer. Virchows Arch 451(4):763–9

    Article  PubMed  CAS  Google Scholar 

  47. Goethals L, Perneel C, Debucquoy A et al (2006) A new approach to the validation of tissue microarrays. J Pathol 208(5):607–14

    Article  PubMed  CAS  Google Scholar 

  48. Torhorst J, Bucher C, Kononen J et al (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159(6):2249–56

    PubMed  CAS  Google Scholar 

  49. Moch H, Schraml P, Bubendorf L et al (1999) High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. Am J Pathol 154(4):981–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology, Hospital do Cancer AC Camargo, Sao Paulo, Brazil

    Glauco Baiocchi

  2. Department of Pelvic Surgery, Hospital do Cancer AC Camargo, Sao Paulo, Brazil

    Ademar Lopes, Benedito M. Rossi, Samuel Aguiar, Gustavo C. Guimarães, Fabio O. Ferreira & Wilson T. Nakagawa

  3. Department of Pathology, Hospital do Cancer AC Camargo, Sao Paulo, Brazil

    Renata A. Coudry & Fernando A. Soares

  4. Departamento de Ginecologia, Hospital do Câncer AC Camargo, Rua Antonio Prudente, 211, 01509-010, Sao Paulo, Brazil

    Glauco Baiocchi

Authors
  1. Glauco Baiocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ademar Lopes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Renata A. Coudry
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benedito M. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Fernando A. Soares
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Samuel Aguiar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gustavo C. Guimarães
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Fabio O. Ferreira
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wilson T. Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glauco Baiocchi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baiocchi, G., Lopes, A., Coudry, R.A. et al. ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Colorectal Dis 24, 1059–1068 (2009). https://doi.org/10.1007/s00384-009-0702-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-009-0702-6

Keywords

Search

Navigation